Close Menu

NEW YORK – AI precision medicine firm Tempus said Thursday that it has raised $200 million in a new Series G2 financing round, which will help expand the company's operations and establish activities in new disease areas including infectious diseases, depression, and cardiology.

Investors in the round included Baillie Gifford, Franklin Templeton, Google, Novo Holdings, and funds and accounts managed by T. Rowe Price. The new raise brings the firm's total financing to approximately $1.05 billion.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.